pSivida is a global bio-nanotech company committed to the development of drug delivery products in the healthcare sector, initially in ophthalmology and oncology.
pSivida is committed to the development of drug delivery products in the healthcare sector, initially in ophthalmology and oncology. pSivida has developed the only two FDA approved sustained release back of the eye treatments for chronic eye disease, Vitrasert® and Retisert®. Both products are manufactured and sold by global ophthalmology company, Bausch & Lomb.
A next generation product, Medidur™ is licensed for ophthalmic applications to Pfizer Inc. Alimera Sciences has also licensed Medidur™ for the treatment of Diabetic Macular Edema, the leading cause of vision loss for Americans under the age of 65, which is presently in fully recruited Phase III clinical trials that is following over 900 patients across the United States, Canada, Europe and India. These trials are being fully funded by our development partner, Alimera Sciences.
pSivida owns the right to develop and commercialize a new biomaterial, nanostructured porous silicon (BioSilicon™), for multiple potential applications in healthcare with a core focus on drug delivery. The lead BioSilicon™ product is BrachySil™, a brachytherapy treatement in Phase II clinical trials, which is being developed for the treatment of inoperable pancreatic cancer.
pSivida's largest shareholder and strategic partner is Pfizer (PFE). QinetiQ (QQ.), the former United Kingdom Government Defence Evaluation & Research Agency (DERA) and Europe's largest research and development organization is a top five shareholder.
pSivida is listed on NASDAQ (PSDV), Australian (PVA), and Frankfurt (PSI) stock exchanges and is a member of the NASDAQ Health Care Index (Nasdaq: IXHC) and the Merrill Lynch Nanotechnology Index.
Level 12 BGC Centre, 28 The Esplanade